Siemens Healthineers wins FDA approval for 3D mammography system
October 2, 2024
The 3D capabilities are part of Siemens’ first completely redesigned mammography platform in over a decade.
The 3D capabilities are part of Siemens’ first completely redesigned mammography platform in over a decade.
Motiva is the first new breast implant to receive premarket approval since 2013, according to Establishment Labs, and enters a market reshaped by safety issues linked to other products.
Femasys today announced it received FDA 510(k) clearance for its FemChec contrast-generating device that checks fallopian tubal status.
For the first time, neuroscientists have developed a way to address debilitating PMS and menstrual pain symptoms without relying on drugs, hormones, or enduring severe side effects.
Women are offered the opportunity to benefit from Carevix at the Peterborough City Hospital – North West Anglia NHS Foundation Trust.
GentleCath Air for Women with FeelClean Technology protects against urethral damage and the risk of UTIs.
Bryan Hsu is tackling an area of research that has long been neglected—menstrual products.
The company’s 8th AI model makes ultrasound easier for new ultrasound users to capture important fetal measurements
ATLANTA, June 20, 2024 (GLOBE NEWSWIRE) — Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces it has received its European Union Medical Device Regulation (EU MDR) certificate and CE Mark certification for four of its products.
Spineart recently announced it received FDA 510(k) clearance for its Scarlet AC-Ti secured anterior cervical cage.